Debiopharm and EORTC announce a collaboration to investigate Triptorelin for treatment of Salivary Gland Cancers
Lausanne, Switzerland – January 13, 2016 – [...]
EORTC study aims to qualify ADC as predictive imaging biomarker in preoperative regimens
Diffusion weighted (DW) magnetic resonance imaging (MRI) is a widely [...]
EORTC welcomes the agreement on the new EU Data Protection Regulation
EORTC welcomes the agreement reached after delicate negotiations by the [...]
EORTC-ETOP trial opens to study pembrolizumab for patients with early stage non-small cell lung cancer
Lung Cancer is the leading cause of cancer-related deaths world-wide. [...]
EORTC hosting session at ICTR-PHE 2016 in Geneva
The EORTC will host a session at ICTR-PHE 2016, the [...]
Can RA-223 improve on Enzalutamide efficacy in patients with early castration resistant prostate cancer?
Globally, prostate cancer is the second most common type of [...]
A risk management plan for functional imaging in cancer clinical trials
In a paper appearing in Lancet Oncology, researchers representing the [...]
Ignyta and EORTC Announce Entrectinib as 1st Investigational Cancer Agent in EORTC SPECTA
SAN DIEGO and BRUSSELS--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a precision [...]
GICC 2016 will highlight primary therapy of early GI cancer with a focus on pancreatic and biliary cancer
The 3rd St. Gallen International Gastrointestinal Cancer Conference, #GICC2016, will [...]
Optimal care for older cancer patients should target relevant HRQOL domains according to EORTC study
In a paper recently published in the European Journal of [...]
